Key Highlights:

  • Eight stocks priced below $1.00 moved between 7.50% and 41.45% on Friday, October 23, 2026, seven higher and one lower.
  • Lucid Diagnostics disclosed first Medicare payments for EsoGuard at $1,938.01 per test and closed a $15.0 million preferred placement.
  • Streamex holds $41.8 million of liquidity, which at the expected $1.1 million monthly burn covers about 38 months (calculated).
  • Sagtec Global and authID face Nasdaq deadlines in February 2027 to restore a $1.00 minimum bid.
  • Cosmos Health at $0.2744 was the lowest-priced name, while Estrella Immunopharma at $0.8085 was the highest.

Which Sub-Dollar Stocks Moved the Most on October 23, 2026?

Eight Nasdaq stocks trading under $1.00 moved sharply on Friday, October 23, 2026, and seven of them rose. 22nd Century Group (NASDAQ:XXII) jumped 41.45% to $0.3051 after preliminary third-quarter revenue of about $4.8 million, and Lucid Diagnostics (NASDAQ:LUCD) gained 24.41% to $0.4077 on Medicare payments. Sagtec Global (NASDAQ:SAGT) rose 12.93% to $0.76, Estrella Immunopharma (NASDAQ:ESLA) 11.24% to $0.8085, Cosmos Health (NASDAQ:COSM) 8.46% to $0.2744, Streamex (NASDAQ:STEX) 8.31% to $0.3870 and Nexus Advanced Technologies (NASDAQ:NXAT) 7.50% to $0.4101. authID (NASDAQ:AUID) fell 14.02% to $0.3018.

22nd Century Group: How Much Did a Sequential Revenue Rebound Matter?

The tobacco harm reduction company reported preliminary, unaudited figures on October 22. Net revenue of about $4.8 million rose roughly 66% from the second quarter, gross profit turned positive at about $0.4 million, and the net loss narrowed to about $2.6 million. Cash was $3.9 million on September 30. Full results are expected on or before November 13, 2026, and the stock sits about 69.5% below $1.00 (calculated). Management has not given numeric guidance and says it is working toward EBITDA breakeven without a timeline.

Lucid Diagnostics: Does Medicare Payment Outweigh a Convertible Preferred Placement?

The esophageal test maker said on October 22 that Medicare began paying $1,938.01 per EsoGuard test, versus about $532 of second-quarter revenue per test (calculated). A $15.0 million Series C placement converts at $0.3519, which could add about 42.6 million shares (calculated). Cash was $33.4 million on June 30, and a final Medicare determination is expected in November. At $0.4077 the equity value is near $75 million (calculated). Second-quarter revenue rose about 26.7% from $1.163 million to $1.474 million (calculated).

Sagtec Global: Can Contract Announcements Close a 24% Gap to the Minimum Bid?

The company has not announced a catalyst. The Malaysian software firm reported first-half revenue up 1% to RM48.5 million, with gross margin widening to 29.0% from 20.1%. A 36-month data center agreement is expected to bring about US$10 million, and a Dubai distributor ordered 1,500 robots worth about US$3 million. Nasdaq set a February 16, 2027 deadline for a $1.00 bid, and the company is weighing a reverse split. The shares closed the August robot-order session 20.41% higher, according to market estimates.

Estrella Immunopharma: What Does a Lymphoma Study Mean for a Nearly Empty Cash Position?

The company has not announced a catalyst. Its STARLIGHT-1 study added a fifth site on October 14, and a first dose-expansion patient received two EB103 infusions on October 15. A summary of the June 30 quarterly report shows cash of $0.1 million, a working capital deficit of $7.4 million and $8.3 million of accrued milestone liabilities. The stock sits about 19.2% below $1.00 (calculated), the smallest gap in this group. Expansion-cohort data and any financing have no announced dates.

Cosmos Health: Is the Lowest Price in the Group Backed by Subscription Growth?

No release is dated October 23. An October 19 update showed 8,940 active U.S. subscriptions, up 42% in five days, and fourth-quarter U.S. revenue is guided to about $15 million. The company reaffirmed 2026 revenue above $90 million, and preliminary nine-month revenue was about $54.3 million. At $0.2744 the shares sit about 72.6% below $1.00 (calculated). No date is set for the quarterly filing.

Streamex: How Does Tokenized Gold Revenue Compare With the Balance Sheet?

The company has not announced a catalyst. Second-quarter revenue was $146 thousand of gold lease income, against a net loss of $14.6 million. Liquidity of $41.8 million includes physical gold, digital assets and cash, and the company reports no debt. Common shares are worth about $45.1 million at the current price, or about 1.08 times liquidity (calculated). Third-quarter results have no announced date. Burn was $1.6 million per month in the second quarter, including about $0.5 million of non-recurring costs.

Nexus Advanced Technologies: What Is Known About the Proposed Defense Merger?

The company has not announced a catalyst. On October 6 it signed an exclusivity agreement on a proposed reverse merger with a U.S. counter-drone technology business valued near $500 million. The target's letters of intent, indicated at about $7 billion, are non-binding. The shares sit about 14.6% below the listed 52-week low of $0.48 (calculated). Earnings are estimated for November 15, 2026, and no definitive agreement date exists. The company was renamed from K Wave Media on September 8, 2026.

authID: How Does a Debenture Conversion Price Frame the Only Decline?

The company has not announced a catalyst. An October 5 private placement of about $1.35 million carries a $0.386 conversion price, and the shares sit about 21.8% below it (calculated). Warrants at $0.50 need stockholder approval. A research summary shows cash of $1.4 million at June 30 and a six-month net loss of $9.2 million. Nasdaq deadlines fall on February 14 and February 23, 2027.

Sub-Dollar Stocks Compared: How Far Below $1.00 Does Each Trade?

Distance from the $1.00 threshold varies widely. Cosmos Health is about 72.6% below it, authID 69.8%, 22nd Century Group 69.5%, Streamex 61.3%, Lucid Diagnostics 59.2% and Nexus Advanced Technologies 59.0%, while Sagtec Global is 24.0% below and Estrella Immunopharma 19.2% (all calculated).

Estrella Immunopharma's price is about 2.9 times Cosmos Health's (calculated). The gap between the best and worst sessions was 55.47 percentage points (calculated), from 22nd Century Group at positive 41.45% to authID at negative 14.02%. The 22nd Century Group gain was about 5.5 times Nexus Advanced Technologies' (calculated).

On funding, Streamex's $41.8 million of liquidity covers about 38 months at its expected $1.1 million monthly burn (calculated). Lucid Diagnostics' $33.4 million of cash equals about 2.9 quarters of its $11.687 million second-quarter loss (calculated), while Estrella Immunopharma reports $0.1 million.

What to Watch Next: Which Deadlines Apply to Sub-Dollar Names?

22nd Century Group expects full third-quarter results on or before November 13, 2026, and Lucid Diagnostics awaits a final Medicare determination in November. Nexus Advanced Technologies has estimated earnings on November 15. authID faces deadlines of February 14 and February 23, 2027, and Sagtec Global has until February 16, 2027. Cosmos Health, Streamex and Estrella Immunopharma have not announced dates for their next reports.

22nd Century Group rose 41.45% to $0.3051 after preliminary third-quarter revenue of about $4.8 million.

authID fell 14.02% to $0.3018, and the company has not announced a catalyst.

Sagtec Global has until February 16, 2027, and authID has until February 23, 2027 for its bid price requirement.